508 related articles for article (PubMed ID: 11207303)
1. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
[TBL] [Abstract][Full Text] [Related]
2. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
Kwant A; Rosenthal KL
Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061
[TBL] [Abstract][Full Text] [Related]
3. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
4. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.
Tengvall S; Lundqvist A; Eisenberg RJ; Cohen GH; Harandi AM
J Virol; 2006 Jun; 80(11):5283-91. PubMed ID: 16699008
[TBL] [Abstract][Full Text] [Related]
5. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
6. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract.
Gallichan WS; Rosenthal KL
Virology; 1996 Oct; 224(2):487-97. PubMed ID: 8874509
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
[TBL] [Abstract][Full Text] [Related]
8. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.
Cortesi R; Ravani L; Rinaldi F; Marconi P; Drechsler M; Manservigi M; Argnani R; Menegatti E; Esposito E; Manservigi R
Int J Pharm; 2013 Jan; 440(2):229-37. PubMed ID: 22743007
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
Görander S; Harandi AM; Lindqvist M; Bergström T; Liljeqvist JÅ
J Virol; 2012 Jul; 86(14):7544-53. PubMed ID: 22553328
[TBL] [Abstract][Full Text] [Related]
12. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization.
Gallichan WS; Rosenthal KL
J Infect Dis; 1998 May; 177(5):1155-61. PubMed ID: 9592997
[TBL] [Abstract][Full Text] [Related]
13. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
Lindqvist M; Persson J; Thörn K; Harandi AM
J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
[TBL] [Abstract][Full Text] [Related]
14. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
[TBL] [Abstract][Full Text] [Related]
15. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus.
Gallichan WS; Rosenthal KL
Vaccine; 1995 Nov; 13(16):1589-95. PubMed ID: 8578847
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
Tengvall S; Josefsson A; Holmgren J; Harandi AM
J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
[TBL] [Abstract][Full Text] [Related]
17. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.
Harandi AM; Eriksson K; Holmgren J
J Virol; 2003 Jan; 77(2):953-62. PubMed ID: 12502811
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
[TBL] [Abstract][Full Text] [Related]
19. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.
Yan Y; Hu K; Fu M; Deng X; Luo S; Tong L; Guan X; He S; Li C; Jin W; Du T; Zheng Z; Zhang M; Liu Y; Hu Q
mSphere; 2021 Apr; 6(2):. PubMed ID: 33910988
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
